AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D).
The investment represents a substantial capital infusion to the $3.5bn announced in November 2024.
The focus of this investment is a manufacturing facility dedicated to producing drug substances for AstraZeneca's weight management and metabolic product range.
This portfolio includes oral glucagon-like peptide-1 (GLP-1), baxdrostat, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) and combination small molecule treatments.
The new facility will be designed to manufacture peptides, small molecules and oligonucleotides.
To be constructed in the Commonwealth of Virginia, the plant will be AstraZeneca’s single manufacturing venture globally.
The new facility will incorporate advanced technologies such as AI, automation and data analytics to enhance production capabilities.
This financial commitment will generate new direct and indirect jobs in the US.
AstraZeneca CEO Pascal Soriot stated: “Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80bn in revenue by 2030.”
The investment also covers other projects: the expansion of AstraZeneca’s R&D facility in Gaithersburg, Maryland, and the establishment of an advanced R&D centre in Kendall Square, Cambridge, Massachusetts.
The company will also develop next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California, as well as expand its continuous manufacturing operations in Mount Vernon, Indiana.
The investment encompasses the expansion of speciality manufacturing in Coppell, Texas, the establishment of new sites to support clinical trials, and an increase in funding for research and development of new medicines.
In July 2025, Modella AI entered a multi-year partnership with AstraZeneca aimed at accelerating AI-driven clinical development in oncology.
“AstraZeneca announces $50bn US investment plans by 2030” was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
